Advanced search
Publication Cover
Expert Review of Vaccines Volume 22, 2023 - Issue 1
Submit an article Journal homepage
3,606
Views
2
CrossRef citations to date
0
Altmetric
Review

Sporozoite immunization: innovative translational science to support the fight against malaria

Thomas L. Richiea Sanaria Inc, Rockville, MD, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2946-5456View further author information
ORCID Icon,
L. W. Preston Churcha Sanaria Inc, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0001-8045-3920View further author information
ORCID Icon,
Tooba Murshedkara Sanaria Inc, Rockville, MD, USAView further author information
,
Peter F. Billingsleya Sanaria Inc, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0003-1142-4813View further author information
ORCID Icon,
Eric R. Jamesa Sanaria Inc, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0002-2184-745XView further author information
ORCID Icon,
Mei-Chun Chena Sanaria Inc, Rockville, MD, USAView further author information
,
Yonas Abebea Sanaria Inc, Rockville, MD, USAView further author information
,
Natasha KCa Sanaria Inc, Rockville, MD, USAView further author information
,
Sumana Chakravartya Sanaria Inc, Rockville, MD, USAView further author information
,
David Dolberga Sanaria Inc, Rockville, MD, USAView further author information
,
Sara A. Healyb Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0003-3078-6094View further author information
ORCID Icon,
Halimatou Diawarac Malaria Research and Training Center, Mali-NIAID ICER, University of Science, Techniques and Technologies of Bamako, Bamako, MaliView further author information
,
Mahamadou S. Sissokoc Malaria Research and Training Center, Mali-NIAID ICER, University of Science, Techniques and Technologies of Bamako, Bamako, MaliORCID Iconhttps://orcid.org/0000-0003-2024-577XView further author information
ORCID Icon,
Issaka Sagarac Malaria Research and Training Center, Mali-NIAID ICER, University of Science, Techniques and Technologies of Bamako, Bamako, MaliORCID Iconhttps://orcid.org/0000-0002-8555-9983View further author information
ORCID Icon,
David M. Cookb Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0009-0002-9965-2799View further author information
ORCID Icon,
Judith E. Epsteinb Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0001-9381-7607View further author information
ORCID Icon,
Benjamin Mordmüllerd Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands;e Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, GermanyORCID Iconhttps://orcid.org/0000-0001-9101-2768View further author information
ORCID Icon,
Melissa Kapuluf Biosciences Department, Kenya Medical Research Institute KEMRI-Wellcome Research Programme, Kilifi, Kenya;g Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UKORCID Iconhttps://orcid.org/0000-0003-0321-7128View further author information
ORCID Icon,
Andrea Kreidenweisse Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany;h German Center for Infection Research (DZIF), partner site Tübingen, Tübingen, GermanyORCID Iconhttps://orcid.org/0000-0002-5025-7221View further author information
ORCID Icon,
Blandine Franke-Fayardi Department of Parasitology, Leiden University Medical Center, Leiden, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-6041-4182View further author information
ORCID Icon,
Selidji T. Agnandjii Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands;j Centre de Recherches Médicales de Lambaréné, Lambaréné, GabonORCID Iconhttps://orcid.org/0000-0003-4693-4207View further author information
ORCID Icon,
María-Silvia A. López Mikuek Ministry of Health and Social Welfare, Government of Equatorial Guinea, Malabo, Equatorial GuineaView further author information
,
Matthew B. B. McCalld Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands;e Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany;j Centre de Recherches Médicales de Lambaréné, Lambaréné, GabonORCID Iconhttps://orcid.org/0000-0002-5738-1401View further author information
ORCID Icon,
Laura Steinhardtl Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USAORCID Iconhttps://orcid.org/0000-0003-0540-9940View further author information
ORCID Icon,
Martina Onekom Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, KenyaORCID Iconhttps://orcid.org/0000-0003-0021-3324View further author information
ORCID Icon,
Ally Olotun Bagamoyo Research and Training Center, Ifakara Health Institute, Bagamoyo, TanzaniaORCID Iconhttps://orcid.org/0000-0001-6696-1937View further author information
ORCID Icon,
Ashley M. Vaughano Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA, USA;p Department of Pediatrics, University of Washington, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0001-5815-756XView further author information
ORCID Icon,
James G. Kublinq Department of Global Health, University of Washington, Seattle, WA, USA;r Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0003-1279-3741View further author information
ORCID Icon,
Sean C. Murphys Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA;t Center for Emerging and Re-emerging Infectious Diseases and Department of Microbiology, University of Washington, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0002-2048-0131View further author information
ORCID Icon,
Said Jongon Bagamoyo Research and Training Center, Ifakara Health Institute, Bagamoyo, TanzaniaView further author information
,
Marcel Tanneru Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland;v University of Basel, Basel, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-1205-6971View further author information
ORCID Icon,
Sodiomon B. Sirimaw Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina FasoORCID Iconhttps://orcid.org/0000-0002-0972-4211View further author information
ORCID Icon,
Matthew B. Laurensx Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0003-3874-581XView further author information
ORCID Icon,
Claudia Daubenbergeru Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland;v University of Basel, Basel, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-7136-0642View further author information
ORCID Icon,
Joana C. Silvay Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA;z Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0001-6502-7026View further author information
ORCID Icon,
Kirsten E. Lykex Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-4966-0830View further author information
ORCID Icon,
Chris J. Jansei Department of Parasitology, Leiden University Medical Center, Leiden, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-6410-6205View further author information
ORCID Icon,
Meta Roestenbergi Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands;aa Department of Infectious Diseases, Leiden University Medical Center, Leiden, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-5052-2830View further author information
ORCID Icon,
Robert W. Sauerweind Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-3163-7202View further author information
ORCID Icon,
Salim Abdullan Bagamoyo Research and Training Center, Ifakara Health Institute, Bagamoyo, TanzaniaView further author information
,
Alassane Dickoc Malaria Research and Training Center, Mali-NIAID ICER, University of Science, Techniques and Technologies of Bamako, Bamako, MaliORCID Iconhttps://orcid.org/0000-0003-2153-8427View further author information
ORCID Icon,
Stefan H. I. Kappeo Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA, USA;p Department of Pediatrics, University of Washington, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0003-1540-1731View further author information
ORCID Icon,
B. Kim Lee Sima Sanaria Inc, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0002-8598-8905View further author information
ORCID Icon,
Patrick E. Duffyb Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0002-4483-5005View further author information
ORCID Icon,
Peter G. Kremsnere Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany;h German Center for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany;j Centre de Recherches Médicales de Lambaréné, Lambaréné, GabonORCID Iconhttps://orcid.org/0000-0002-3926-4113View further author information
ORCID Icon &
Stephen L. Hoffmana Sanaria Inc, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0002-0700-9505View further author information
ORCID Icon show all
Pages 964-1007 | Received 31 Dec 2022, Accepted 04 Aug 2023, Published online: 11 Aug 2023

References

  • Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013 Sep 20;341(6152):p. 1359–1365.
  • Jongo SA, Church LWP, Mtoro AT, et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. Clin Infect Dis. 2020 Nov 29;71(11):p. 2849–2857.
  • Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect Dis. 2022 Nov 18;22(3):p. 377–389.
  • Ishizuka AS, Lyke KE, DeZure A, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016 May 9;22(6):p. 614–623.
  • Lyke KE, Ishizuka AS, Berry AA, et al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017 Mar 07;114(10):p. 2711–2716.
  • Mordmüller B, Sulyok Z, Sulyok M, et al. A PfSPZ Vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022 Aug 23;7(1):100. doi: 10.1038/s41541-022-00510-z
  • Sirima SB, Ouédraogo A, Tiono AB, et al. A randomized controlled trial showing safety and durable efficacy of a whole sporozoite vaccine against endemic malaria. Sci Transl Med. 2022;14(674):p. eabj3776.
  • Mordmüller B, Surat G, Lagler H, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017 Feb 23;542(7642):p. 445–449.
  • Eappen AG, Li T, Marquette M, et al. In vitro production of infectious Plasmodium falciparum sporozoites. Nature. 2022;612(7940):p. 534–539.
  • Sergent E, Sergent E. Sur l’immunité dans le paludisme des oiseaux. Conservation in vitro des sporozoites de Plasmodium relictum. Immunité relative obtenue par inoculation de ces sporozoites. CR Acad Sci. 1910;151:407–409.
  • Mulligan HW, Russell P, Mohan BN. Active immunization of fowls against Plasmodium gallinaceum by injections of killed homologous sporozoites. J Malaria Inst India. 1941;4:25–34.
  • Russell PF, Mohan BN. The immunization of fowls against mosquito-borne Plasmodium gallinaceum by injections of serum and of inactivated homologous sporozoites. J Exp Med. 1942 Nov 1;76(5):477–495.
  • Freund J, Thomson KJ, Sommer HE, et al. Immunization of rhesus monkeys against malaria infection (P. knowlesi) with killed parasites and adjuvants. Science. 1945 Aug 24;102(2643):202–204.
  • Freund J, Sommer HE, Walter AW. Immunization against malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science. 1945 Aug 24;102(2643):200–202.
  • Richards WGH. Active immunization of chicks against Plasmodium gallinacium by inactivated homologous sporozoites and erythrocytic parasites. Nature. 1966;212(5069):1492–1494. doi: 10.1038/2121492a0
  • Nussenzweig RS, Vanderberg J, Most H, et al. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature. 1967;216(5111):160–162. doi: 10.1038/216160a0
  • Clyde DF, McCarthy VC, Miller RM, et al. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci. 1973;266(6):398–403. doi: 10.1097/00000441-197312000-00001
  • Clyde DF, Most H, McCarthy VC, et al. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973;266(3):169–177. doi: 10.1097/00000441-197309000-00002
  • Clyde DF, McCarthy VC, Miller RM, et al. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975;24(3):397–401. doi: 10.4269/ajtmh.1975.24.397
  • McCarthy VC, Clyde DF. Plasmodium vivax: Correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol. 1977;41(1):167–171. doi: 10.1016/0014-4894(77)90142-4
  • Clyde DF. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ. 1990;68(Suppl):9–12.
  • Rieckmann KH, Carson PE, Beaudoin RL, et al. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1974;68(3):258–259. doi: 10.1016/0035-9203(74)90129-1
  • Rieckmann KH, Beaudoin RL, Cassells JS, et al. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ. 1979;57 Suppl 1(Suppl):261–265.
  • Rieckmann KH. Human immunization with attenuated sporozoites. Bull World Health Organ. 1990;68 Suppl(Suppl):13–16.
  • Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002 Apr 15;185(8):1155–1164. doi: 10.1086/339409
  • Collins WE, Contacos PG. Immunization of monkeys against Plasmodium cynomolgi by X-irradiated sporozoites. Nat New Biol. 1972 Apr 12;236(67):176–177.
  • Gwadz RW, Cochrane AH, Nussenzweig V, et al. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;57 Suppl 1(Suppl):165–173.
  • Jordan-Villegas A, Perdomo AB, Epstein JE, et al. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):43–50. doi: 10.4269/ajtmh.2011.09-0759
  • Hoffman SL, Isenbarger D, Long GW, et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science. 1989 Jun 2;244(4908):1078–1081. doi: 10.1126/science.2524877
  • Weiss WR, Mellouk S, Houghten RA, et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med. 1990 Mar 1;171(3):763–773. doi: 10.1084/jem.171.3.763
  • Romero P, Maryanski JL, Corradin G, et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature. 1989;341(6240):323–325. doi: 10.1038/341323a0
  • Rodrigues MM, Cordey A-S, Arreaza G, et al. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol. 1991;3(6):579–585. doi: 10.1093/intimm/3.6.579
  • Khusmith S, Sedegah M, Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun. 1994 Jul;62(7):2979–2983. doi: 10.1128/iai.62.7.2979-2983.1994
  • Guebre-Xabier M, Schwenk R, Krzych U. Memory phenotype CD8(+) T cells persist in livers of mice protected against malaria by immunization with attenuated Plasmodium berghei sporozoites. Eur J Immunol. 1999 Dec;29(12):3978–3986. doi: 10.1002/(SICI)1521-4141(199912)29:12<3978:AID-IMMU3978>3.0.CO;2-0
  • Weiss WR, Sedegah M, Beaudoin RL, et al. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A. 1988;85(2):573–576. doi: 10.1073/pnas.85.2.573
  • Weiss WR, Berzofsky JA, Houghten RA, et al. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol. 1992 Sep 15;149(6):2103–2109.
  • Schofield L, Villaquiran J, Ferreira A, et al. γ interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature. 1987;330(6149):664–666. doi: 10.1038/330664a0
  • Doolan DL, Hoffman SL. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol. 1999 Jul 15;163(2):884–892.
  • Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol. 2000 Aug 1;165(3):1453–1462.
  • Trimnell A, Takagi A, Gupta M, et al. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol. 2009 Nov 1;183(9):5870–5878.
  • Krzych U, Dalai S, Zarling S, et al. Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol. 2012;3:370. doi: 10.3389/fimmu.2012.00370
  • Weiss WR, Jiang CG, Gruner AC. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One. 2012;7(2):e31247. doi: 10.1371/journal.pone.0031247
  • Rodrigues M, Nussenzweig RS, Zavala F. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology. 1993;80:1–5.
  • Belnoue E, Costa FTM, Frankenberg T, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol. 2004;172(4):2487–2495. doi: 10.4049/jimmunol.172.4.2487
  • Overstreet MG, Chen YC, Cockburn IA, et al. CD4+ T cells modulate expansion and survival but not functional properties of effector and memory CD8+ T cells induced by malaria sporozoites. PLoS One. 2011 Jan 4;6(1):e15948.
  • Weiss WR, Sedegah M, Berzofsky JA, et al. The role of CD4+ T cells in immunity to malaria sporozoites. J Immunol. 1993 Sep 1;151(5):2690–2698.
  • Malik A, Egan JE, Houghten RA, et al. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3300–3304. doi: 10.1073/pnas.88.8.3300
  • Wizel B, Houghten RA, Parker KC, et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med. 1995 Nov 1;182(5):1435–1445.
  • Doolan DL, Hoffman SL, Southwood S, et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity. 1997 Jul;7(1):97–112. doi: 10.1016/S1074-7613(00)80513-0
  • Doolan DL, Southwood S, Freilich DA, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9952–9957.
  • Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science. 2011 Oct 28;334(6055):475–480. doi: 10.1126/science.1211548
  • Berenzon D, Schwenk RJ, Letellier L, et al. Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. J Immunol. 2003 Aug 15;171(4):2024–2034.
  • Frevert U, Nardin E. Cellular effector mechanisms against Plasmodium liver stages. Cell Microbiol. 2008 Oct;10(10):1956–1967. doi: 10.1111/j.1462-5822.2008.01211.x
  • Tse SW, Cockburn IA, Zhang H, et al. Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun. 2013 Jul;14(5):302–309. doi: 10.1038/gene.2013.20
  • Olsen TM, Stone BC, Chuenchob V, et al. Prime-and-trap malaria vaccination to generate protective CD8(+) liver-resident memory T cells. J Immunol. 2018 Oct 1;201(7):1984–1993.
  • Walk J, Stok JE, Sauerwein RW. Can patrolling liver-resident T cells control human malaria parasite development? Trends Immunol. 2019 Mar;40(3):186–196. doi: 10.1016/j.it.2019.01.002
  • Fernandez-Ruiz D, Ng WY, Holz LE, et al. Liver-resident memory CD8+ T cells form a front-line defense against malaria liver-stage infection. Immunity. 2016 Oct 18;45(4):889–902.
  • Lefebvre MN, Harty JT. You shall not pass: memory CD8 T cells in liver-stage malaria. Trends Parasitol. 2020 Feb;36(2):147–157. doi: 10.1016/j.pt.2019.11.004
  • Tarun AS, Peng X, Dumpit RF, et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):305–310.
  • Caldelari R, Dogga S, Schmid MW, et al. Transcriptome analysis of Plasmodium berghei during exo-erythrocytic development. Malar J. 2019 Sep 24;18(1):330.
  • Murphy SC, Kas A, Stone BC, et al. A T-cell response to a liver-stage Plasmodium antigen is not boosted by repeated sporozoite immunizations. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6055–6060.
  • Goswami D, Minkah NK, Kappe SHI. Malaria parasite liver stages. J Hepatol. 2022 Mar;76(3):735–737. doi: 10.1016/j.jhep.2021.05.034
  • Limbach K, Aguiar J, Gowda K, et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malar J. 2011;10(1):65. doi: 10.1186/1475-2875-10-65
  • Aguiar JC, Bolton J, Wanga J, et al. Discovery of novel Plasmodium falciparum pre-erythrocytic antigens for vaccine development. PLoS One. 2015;10(8):e0136109. doi: 10.1371/journal.pone.0136109
  • Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017 Feb 16;17(5):498–509. doi: 10.1016/S1473-3099(17)30104-4
  • Zaidi I, Diallo H, Conteh S, et al. Gammadelta T cells are required for the induction of sterile immunity during irradiated sporozoite vaccinations. J Immunol. 2017 Dec 1;199(11):3781–3788.
  • Howard J, Zaidi I, Loizon S, et al. Human Vγ9Vδ2 T lymphocytes in the immune response to P. falciparum infection. Front Immunol. 2018;9:2760. doi: 10.3389/fimmu.2018.02760
  • Mwakingwe-Omari A, Healy SA, Lane J, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021 Jul;595(7866):289–294. doi: 10.1038/s41586-021-03684-z
  • Duffy FJ, Hertoghs N, Du Y, et al. Longitudinal immune profiling after radiation-attenuated sporozoite vaccination reveals coordinated immune processes correlated with malaria protection [original Research]. Front Immunol. 2022 [2022 Dec 15];13. doi: 10.3389/fimmu.2022.1042741
  • Walk J, Sauerwein RW. Activatory receptor NKp30 predicts NK cell activation during controlled human malaria infection. Front Immunol. 2019;10:2864. doi: 10.3389/fimmu.2019.02864
  • Walk J, de Bree LCJ, Graumans W, et al. Outcomes of controlled human malaria infection after BCG vaccination. Nat Commun. 2019 Feb 20;10(1):874.
  • Zenklusen I, Jongo S, Abdulla S, et al. Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies. The J Infect Dis. 2018 Feb 8;217(10):1569–1578.
  • Suscovich TJ, Fallon JK, Das J, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. 2020;12(553):eabb4757. doi: 10.1126/scitranslmed.abb4757
  • Aliprandini E, Tavares J, Panatieri RH, et al. Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin. Nat Microbiol. 2018 Nov;3(11):1224–1233. doi: 10.1038/s41564-018-0254-z
  • Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22(1):13–36. doi: 10.1128/CMR.00025-08
  • Offeddu V, Thathy V, Marsh K, et al. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol. 2012 May 15;42(6):535–548.
  • Hoffman SL, Oster CN, Plowe CV, et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science. 1987 Aug 7;237(4815):639–642.
  • Owusu-Agyei S, Koram KA, Baird JK, et al. Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am J Trop Med Hyg. 2001 Sep;65(3):197–203. doi: 10.4269/ajtmh.2001.65.197
  • FDA. Vaccines licensed for use in the United States. 2022. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
  • Yap XZ, McCall MBB, Sauerwein RW. Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model. Immunol Rev. 2020 Jan;293(1):253–269. doi: 10.1111/imr.12811
  • CDC. Yellow fever vaccine recommendations. Available at https://www.cdc.gov/yellowfever/vaccine/vaccine-recommendations.html.2021.
  • Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013 Sep;89(3):434–444. doi: 10.4269/ajtmh.13-0264
  • Roestenberg M, Teirlinck AC, McCall MB, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011 May 21;377(9779):1770–1776. doi: 10.1016/S0140-6736(11)60360-7
  • Teirlinck AC, McCall MB, Roestenberg M, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans [journal article Research support non-U S gov’t]. PLOS Pathogens. 2011 Dec;7(12):e1002389. doi: 10.1371/journal.ppat.1002389
  • Zarling S, Berenzon D, Dalai S, et al. The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria. J Immunol. 2013 May 15;190(10):5128–5141.
  • Pradel G, Garapaty S, Frevert U. Kupffer and stellate cell proteoglycans mediate malaria sporozoite targeting to the liver. Comp Hepatol. 2004 Jan 14;3(Suppl 1):S47.
  • Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol. 2003 Nov;206(Pt 21):3803–3808. doi: 10.1242/jeb.00644
  • Hoffman SL, Billingsley P, James E, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccines. 2010;6(1):97–106. doi: 10.4161/hv.6.1.10396
  • Ballou WR, Hoffman SL, Sherwood JA, et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987 Jun 6;1(8545):1277–1281.
  • Sedegah M, Beaudoin RL, Majarian WR, et al. Evaluation of vaccines designed to induce protective cellular immunity against the Plasmodium yoelii circumsporozoite protein: vaccinia, pseudorabies, and Salmonella transformed with circumsporozoite gene. Bull World Health Organ. 1990;68(Suppl):109–114.
  • Sedegah M, Chiang CH, Weiss WR, et al. Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. Vaccine. 1992;10(9):578–584. doi: 10.1016/0264-410X(92)90436-N
  • Wang HH, Rogers WO, Kang YH, et al. Partial protection against malaria by immunization with Leishmania enriettii expressing the Plasmodium yoelii circumsporozoite protein. Mol Biochem Parasitol. 1995 Feb;69(2):139–148. doi: 10.1016/0166-6851(94)00159-K
  • Sedegah M, Hedstrom R, Hobart P, et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9866–9870. doi: 10.1073/pnas.91.21.9866
  • Richie TL, Charoenvit Y, Wang R, et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Human Vaccines Immunother. 2012;8(11):1564–1584. doi: 10.4161/hv.22129
  • Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998 Oct 16;282(5388):476–480.
  • Sedegah M, Tamminga C, McGrath S, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One. 2011;6(10):e24586. doi: 10.1371/journal.pone.0024586
  • Tamminga C, Sedegah M, Regis D, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One. 2011;6(10):e25868. doi: 10.1371/journal.pone.0025868
  • Sedegah M, Jones TR, Kaur M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7648–7653.
  • Epstein JE, Charoenvit Y, Kester KE, et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS, S/AS02A. Vaccine. 2004 Apr 16;22(13–14):1592–1603.
  • Chuang I, Sedegah M, Cicatelli S, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571
  • Sedegah M, Kim Y, Peters B, et al. Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar J. 2010 Aug 24;9(1):241.
  • Sedegah M, Kim Y, Ganeshan H, et al. Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malar J. 2013;12(1):185. doi: 10.1186/1475-2875-12-185
  • Davies L “Ghana is first country to approve Oxford malaria vaccine.” The Guardian, 13 APR 2023, https://www.theguardian.com/global-development/2023/apr/13/ghana-is-first-country-to-approve-oxford-r21-malaria-vaccine.
  • Dzirutwe M “Nigeria regulator grants approval to Oxford’s malaria vaccine.” Reuters, 17 APR 2023, https://www.reuters.com/world/africa/nigeria-regulator-grants-approval-oxfords-malaria-vaccine-2023-04-17/
  • Regules JA, Cicatelli SB, Bennett JW, et al. Fractional third and Fourth dose of RTS,S/AS01 malaria candidate vaccine: A Phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016 Sep 1;214(5):762–771.
  • Moon JE, Ockenhouse C, Regules JA, et al. A Phase IIa controlled human malaria infection and immunogenicity study of RTS,S/AS01E and RTS,S/AS01B delayed fractional dose regimens in malaria-naive adults. J Infect Dis. 2020 Oct 13;222(10):1681–1691.
  • Datoo MS, Natama MH, Somé A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021 May 5;397(10287):1809–1818.
  • Morzaria S, Williamson S Live vaccines for Theileria parva- deployment in eastern, central and southern Africa - Proceedings of an FAO/OAU-IBAR/ILRI workshop held at ILRI, Nairobi, Kenya. In: ILRI (International Livestock Research Institute); Nairobi, Kenya, p. 166. 1999 10-12 Mar 1997.
  • Steinaa L, Svitek N, Awino E, et al. Immunization with one Theileria parva strain results in similar level of CTL strain-specificity and protection compared to immunization with the three-component Muguga cocktail in MHC-matched animals. BMC Vet Res. 2018 May 2;14(1):145.
  • Moser KA, Drabek EF, Dwivedi A, et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med. 2020 Jan 8;12(1):6.
  • Silva JC, Dwivedi A, Moser KA, et al. Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nat Commun. 2022 Jun 13;13(1):3390. doi: 10.1038/s41467-022-30882-8
  • Diawara H. Phase 2 safety and efficacy evaluation of radiation attenuated Plasmodium falciparum sporozoite (PfSPZ) vaccine in healthy African adult women of childbearing potential in Ouélessébougou, Mali. Annual Meeting of the American Society of Tropical Medicine and Hygiene. Oral presentation on Friday, Nov 19, 2021 at 11: 05 am. Am J Trop Med Hyg. 2021 Nov;105(5):Abstract 0294, 93.
  • Roestenberg M, Bijker EM, Sim BK, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2013 Jan;88(1):5–13. doi: 10.4269/ajtmh.2012.12-0613
  • Mordmüller B, Supan C, Sim KL, et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015;14(1):117. doi: 10.1186/s12936-015-0628-0
  • Garcia CR, Manzi F, Tediosi F, et al. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine. 2013 Jan 2;31(2):380–386. doi: 10.1016/j.vaccine.2012.10.109
  • James ER. Disrupting vaccine logistics. Int Health. 2021 Apr 27;13(3):211–214.
  • Sheehy SH, Spencer AJ, Douglas AD, et al. Optimising controlled human malaria infection studies using cryopreserved P. falciparum parasites administered by needle and syringe. PLoS One. 2013;8(6):e65960. doi: 10.1371/journal.pone.0065960
  • Hodgson SH, Juma EA, Salim A, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection [clinical trial]. Front Microbiol. 2014 Dec 12;5:686.
  • Shekalaghe S, Rutaihwa M, Billingsley PF, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014 Sep 3;91(3):471–480. doi: 10.4269/ajtmh.14-0119
  • Gomez-Perez GP, Legarda A, Munoz J, et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14(1):306. doi: 10.1186/s12936-015-0817-x
  • Lyke KE, Laurens MB, Strauss K, et al. Optimizing intradermal administration of cryopreserved Plasmodium falciparum sporozoites in controlled human malaria infection. Am J Trop Med Hyg. 2015 Sep 28;93(6):1274–1284.
  • Bastiaens GJ, van Meer MP, Scholzen A, et al. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg. 2016 Dec 28;94(3):663–673.
  • Laurens MB, Berry AA, Travassos MA, et al. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. J Infect Dis. 2019 Aug 16;220(12):1962–1966.
  • Jongo SA, Shekalage SA, Church LWP, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018 Jun 25;99(2):338–349.
  • Dejon-Agobe JC, Ateba-Ngoa U, Lalremruata A, et al. Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin Infect Dis. 2019 Dec 18;69(8):1377–1384.
  • Jongo SA, Urbano V, Church LWP, et al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in Equatoguinean adults. Am J Trop Med Hyg. 2021 Jan;104(1):283–293. doi: 10.4269/ajtmh.20-0435
  • Murphy SC, Deye GA, Sim BKL, et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: a randomized, placebo-controlled trial with controlled human malaria infection. PLOS Pathog. 2021 May;17(5):e1009594. doi: 10.1371/journal.ppat.1009594
  • Sulyok Z, Fendel R, Eder B, et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021 May 4;12(1):2518.
  • Jongo SA, Church LWP, Nchama V, et al. Multi-dose priming regimens of PfSPZ Vaccine: safety and efficacy against controlled human malaria infection in Equatoguinean adults. Am J Trop Med Hyg. 2022 Feb 7;106(4):1215–1226.
  • Sulyok M, Ruckle T, Roth A, et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017 Mar 28;17(6):636–644.
  • Murphy SC, Duke ER, Shipman KJ, et al. A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation. J Infect Dis. 2018 Feb 14;217(5):693–702.
  • Lell B, Mordmüller B, Dejon Agobe JC, et al. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg. 2018 Feb;98(2):508–515. doi: 10.4269/ajtmh.17-0343
  • Achan J, Reuling I, Yap XZ, et al. Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a Plasmodium falciparum controlled human infection. Clin Infect Dis. 2019 Aug 12;70(12):2544–2552.
  • Kapulu MC, Njuguna P, Hamaluba MM. Controlled human malaria infection in semi-immune Kenyan adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity. Wellcome Open Res. 2019;3:155. doi: 10.12688/wellcomeopenres.14909.2
  • Kapulu MC, Njuguna P, Hamaluba M, et al. Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection. JCI Insight. 2021 Sep 8;6(17). doi: 10.1172/jci.insight.146443
  • Jongo SA, Church LWP, Mtoro AT, et al. Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ Vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am J Trop Med Hyg. 2019 Jun;100(6):1433–1444. doi: 10.4269/ajtmh.18-0835
  • Steinhardt LC, Richie TL, Yego R, et al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin Infect Dis. 2020 Sep 26;71(14):1063–1071.
  • Oneko M, Cherop YR, Sang T, et al. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. Vaccine. 2020 Jun 15;38(29):4592–4600. doi: 10.1016/j.vaccine.2020.05.008
  • Achieng F, Rosen JG, Cherop RY, et al. Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya. Malar J. 2020 Jun 24;19(1):226.
  • Gola A, Silman D, Walters AA, et al. Prime and target immunization protects against liver-stage malaria in mice. Sci Transl Med. 2018 Sep 26;10(460). doi: 10.1126/scitranslmed.aap9128
  • Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. 2020 Jan;577(7788):95–102. doi: 10.1038/s41586-019-1817-8
  • van Buskirk KM, O’Neill MT, De La Vega P, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci, USA. 2009;106(31):13004–13009. doi: 10.1073/pnas.0906387106
  • Murphy SC, Vaughan AM, Kublin JG, et al. A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection. Sci Transl Med. 2022 Aug 24;14(659):eabn9709.
  • Butler NS, Schmidt NW, Vaughan AM, et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe. 2011 Jun 16;9(6):451–462.
  • Goswami D, Betz W, Locham NK, et al. A replication-competent late liver stage–attenuated human malaria parasite. JCI Insight. 2020 Aug 26;5(13):e135589. doi: 10.1172/jci.insight.135589
  • Roestenberg M, Walk J, van der Boor SC, et al. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med. 2020 May 20;12(544):eaaz5629. doi: 10.1126/scitranslmed.aaz5629
  • Franke-Fayard B. Development and clinical evaluation of genetically attenuated parasite that arrests late in the liver. In: Oral presentation Tues, Nov 1, 10:45 am, 2022 Annual Meeting of the American Society for Tropical Medicine and Hygiene, Seattle, Washington. 2022.
  • James ER, Wen Y, Overby J, et al. Cryopreservation of Anopheles stephensi embryos. Sci Rep. 2022 Jan 7;12(1):43.
  • Phalen H, Vagdargi P, Schrum ML, et al. A mosquito Pick-and-Place system for PfSPZ-based malaria vaccine production. IEEE Trans Autom Sci Eng. 2021 Jan;18(1):299–310. doi: 10.1109/TASE.2020.2992131
  • Blight J, Sala KA, Atcheson E, et al. Dissection-independent production of a protective whole-sporozoite malaria vaccine. bioRxiv. 2020:2020.06.22.164756.
  • Warburg A, Miller LH. Sporogonic development of a malaria parasite in vitro. Science. 1992 Jan 24;255(5043):448–450.
  • Imkeller K, Scally SW, Bosch A, et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science. 2018 Jun 7;360(6395):1358–1362.
  • Kisalu NK, Idris AH, Weidle C, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018 May;24(4):408–416. doi: 10.1038/nm.4512
  • Tan J, Sack BK, Oyen D, et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat Med. 2018 May;24(4):401–407. doi: 10.1038/nm.4513
  • Wu RL, Idris AH, Berkowitz NM, et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N Engl J Med. 2022 Aug 4;387(5):397–407.
  • Gaudinski MR, Berkowitz NM, Idris AH, et al. A monoclonal antibody for malaria prevention. N Engl J Med. 2021 Aug 26;385(9):803–814.
  • Kayentao K, Ongoiba A, Preston AC, et al. Safety and efficacy of a monoclonal antibody against malaria in Mali. N Engl J Med. 2022 Nov 17;387(20):1833–1842.
  • Vaughan AM, Mikolajczak SA, Wilson EM, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest. 2012 Oct 1;122(10):3618–3628.
  • Frischknecht F, Matuschewski K. Plasmodium sporozoite biology. Cold Spring Harb Perspect Med. 2017 May 1;7(5):a025478.
  • Vaughan AM, Kappe SHI. Malaria parasite liver infection and exoerythrocytic biology. Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):a025486.
  • Nganou-Makamdop K, Sauerwein RW. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better? Trends Parasitol. 2013 Jun;29(6):304–310. doi: 10.1016/j.pt.2013.03.008
  • Olotu A, Urbano V, Hamad A, et al. Advancing Global Health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in healthy Equatoguinean men. Am J Trop Med Hyg. 2018 Oct 30;98(1):308–318.
  • Lyke KE, Singer A, Berry AA, et al. Multidose priming and delayed boosting improve PfSPZ Vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin Infect Dis. 2021 Sep 12;73(7):e2424–e2435.
  • Oneko M, Steinhardt LC, Yego R, et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021 Sep;27(9):1636–1645. doi: 10.1038/s41591-021-01470-y
  • Spring M, Murphy J, Nielsen R, et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine. 2013 Oct 9;31(43):4975–4983. doi: 10.1016/j.vaccine.2013.08.007
  • Kublin JG, Mikolajczak SA, Sack BK, et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med. 2017 Jan 4;9(371):eaad9099.
  • Coulibaly D, Kone AK, Traore K, et al. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial. EClinicalMedicine. 2022 Oct;52:101579.
  • Borrmann S, Sulyok Z, Müller K, et al. Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy. bioRxiv. 2020:2020.09.14.296152.
  • Goswami D, Minkah NK, Kappe SHI. Designer parasites: Genetically engineered Plasmodium as vaccines to prevent malaria infection. J Immunol. 2019 Jan 1;202(1):20–28.
  • Franke-Fayard B, Marin-Mogollon C, Geurten FJA, et al. Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver. NPJ Vaccines. 2022 Nov 4;7(1):139.
  • Sim BKL Development and clinical evaluation of genetically attenuated, replication competent, late arresting (LARC) PfSPZ vaccines manufactured in mosquitoes or in vitro using bioreactors. In: Oral presentation Tues, Nov 1, 11:25 am, 2022 Annual Meeting of the American Society for Tropical Medicine and Hygiene, Seattle, Washington.
  • Mueller AK, Camargo N, Kaiser K, et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):3022–3027.
  • Labaied M, Harupa A, Dumpit RF, et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun. 2007 Aug;75(8):3758–3768. doi: 10.1128/IAI.00225-07
  • Hempelmann E, Krafts K. Bad air, amulets and mosquitoes: 2,000 years of changing perspectives on malaria. Malar J. 2013 Jul 9;12(1):232.
  • Hickey BW, Lumsden JM, Reyes S, et al. Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malar J. 2016;15(1):377. doi: 10.1186/s12936-016-1435-y
  • Jin Y, Kebaier C, Vanderberg J. Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect Immun. 2007 Nov;75(11):5532–5539. doi: 10.1128/IAI.00600-07
  • Choumet V, Attout T, Chartier L, et al. Visualizing non infectious and infectious Anopheles gambiae blood feedings in naive and saliva-immunized mice. PLoS One. 2012;7(12):e50464. doi: 10.1371/journal.pone.0050464
  • Gueirard P, Tavares J, Thiberge S, et al. Development of the malaria parasite in the skin of the mammalian host. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18640–18645.
  • Haeberlein S, Chevalley-Maurel S, Ozir-Fazalalikhan A, et al. Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load. Sci Rep. 2017 Sep 4;7(1):10372.
  • Guilbride DL, Guilbride PD, Gawlinski P. Malaria’s deadly secret: a skin stage. Trends Parasitol. 2012 Apr;28(4):142–150. doi: 10.1016/j.pt.2012.01.002
  • Winkel BMF, Pelgrom LR, van Schuijlenburg R, et al. Plasmodium sporozoites induce regulatory macrophages. PLOS Pathog. 2020 Sep;16(9):e1008799. doi: 10.1371/journal.ppat.1008799
  • Amino R, Thiberge S, Martin B, et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat Med. 2006 Feb;12(2):220–224. doi: 10.1038/nm1350
  • Chakravarty S, Cockburn IA, Kuk S, et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat Med. 2007;13(9):1035–1041. doi: 10.1038/nm1628
  • Spitalny GL, Nussenzweig RS Effect of various routes of immunization and methods of parasite attenuation on the development of protection against sporozoite-induced rodent malaria. In: Proceedings of the Helminthological Society of Washington, Washington, BC; 39. 506–514. 1972.
  • Beaudoin RL, Strome CPA, Mitchell F, et al. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol. 1977;42(1):1–5. doi: 10.1016/0014-4894(77)90054-6
  • Hodgson SH, Juma E, Salim A, et al. Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. Malar J. 2015 Jan 28;14(1):182.
  • Epstein JE, Paolino KM, Richie TL, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. 2017 Jan 12;2(1):e89154. doi: 10.1172/jci.insight.89154
  • Burkot TR, Williams JL, Schneider I. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg. 1984;78(3):339–341. doi: 10.1016/0035-9203(84)90114-7
  • Delemarre BJ, van der Kaay HJ. Tropical malaria contracted the natural way in the Netherlands. Ned Tijdschr Geneeskd. 1979 Nov 17;123(46):1981–1982.
  • Ponnudurai T, Leeuwenberg AD, Meuwissen JH. Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture. Trop Geogr Med. 1981;33(1):50–54.
  • Preston MD, Campino S, Assefa SA, et al. A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nat Commun. 2014 Jun 13;5(1):4052.
  • Wahid R, Fresnay S, Levine MM, et al. Immunization with Ty21a live oral typhoid vaccine elicits cross reactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans. Mucosal Immunol. 2015 Nov;8(6):1349–1359. doi: 10.1038/mi.2015.24
  • Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049–1052.
  • Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015 Dec 22;282(1821):20143085.
  • Fried M, Duffy PE. Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine. 2015 Dec 22;33(52):7483–7488.
  • Healy SA, Fried M, Richie T, et al. Malaria vaccine trials in pregnant women: an imperative without precedent. Vaccine. 2019 Feb 4;37(6):763–770.
  • Gamain B, Chêne A, Viebig NK, et al. Progress and insights toward an effective placental malaria vaccine. Front Immunol. 2021;12:634508. doi: 10.3389/fimmu.2021.634508
  • Orjih AU, Cochrane AH, Nussenzweig RS. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. Trans R Soc Trop Med Hyg. 1982;76(1):57–61. doi: 10.1016/0035-9203(82)90019-0
  • Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468–477. doi: 10.1056/NEJMoa0805832
  • Bijker EM, Teirlinck AC, Schats R, et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis. 2014 Nov 15;210(10):1605–1615.
  • Schats R, Bijker EM, van Gemert GJ, et al. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS One. 2015;10(5):e0124243. doi: 10.1371/journal.pone.0124243
  • Bijker EM, Schats R, Obiero JM, et al. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS One. 2014;9(11):e112910. doi: 10.1371/journal.pone.0112910
  • Ibanez J, Fendel R, Lorenz FR, et al. Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens. NPJ Vaccines. 2022 May 31;7(1):59.
  • Healy SA, Murphy SC, Hume JCC, et al. Chemoprophylaxis vaccination: phase I study to explore stage-specific immunity to Plasmodium falciparum in US adults. Clin Infect Dis. 2020 Sep 12;71(6):1481–1490.
  • Friesen J, Silvie O, Putrianti ED, et al. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med. 2010 Jul 14;2(40):40ra49.
  • Mueller AK, Labaied M, Kappe SH, et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005 Jan 13;433(7022):164–167. doi: 10.1038/nature03188
  • Tarun AS, Dumpit RF, Camargo N, et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis. 2007;196(4):608–616. doi: 10.1086/519742
  • van Dijk MR, Douradinha B, Franke-Fayard B, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12194–12199. doi: 10.1073/pnas.0500925102
  • Ishino T, Chinzei Y, Yuda M. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol Microbiol. 2005 Dec;58(5):1264–1275. doi: 10.1111/j.1365-2958.2005.04801.x
  • Douradinha B, van Dijk MR, Ataide R, et al. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. Int J Parasitol. 2007 Nov;37(13):1511–1519. doi: 10.1016/j.ijpara.2007.05.005
  • Annoura T, van Schaijk BC, Ploemen IH, et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J. 2014 Feb 7;28(5):2158–2170.
  • van Schaijk BC, Ploemen IH, Annoura T, et al. A genetically attenuated malaria vaccine candidate based on gene-deficient sporozoites. Elife. 2014 Nov 19;3:e03582. doi:10.7554/eLife.03582
  • Aly AS, Mikolajczak SA, Rivera HS, et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol. 2008 Jul;69(1):152–163. doi: 10.1111/j.1365-2958.2008.06271.x
  • Silvie O, Goetz K, Matuschewski K, et al. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLOS Pathogens. 2008 Jun;4(6):e1000086. doi: 10.1371/journal.ppat.1000086
  • Othman AS, Marin-Mogollon C, Salman AM, et al. The use of transgenic parasites in malaria vaccine research. Expert Rev Vaccines. 2017 Jul;16(7):1–13. doi: 10.1080/14760584.2017.1333426
  • Jobe O, Lumsden J, Mueller AK, et al. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex class I-dependent interferon-gamma-producing CD8+ T cells. J Infect Dis. 2007 Aug 15;196(4):599–607.
  • van Schaijk BCL, Janse CJ, van Gemert GJ, et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One. 2008;3(10):e3549. doi: 10.1371/journal.pone.0003549
  • Mikolajczak SA, Lakshmanan V, Fishbaugher M, et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther. 2014 Sep;22(9):1707–1715. doi: 10.1038/mt.2014.85
  • Kreutzfeld O, Müller K, Matuschewski K. Engineering of genetically arrested parasites (GAPs) for a precision malaria vaccine. Front Cell Infect Microbiol. 2017;7:198. doi: 10.3389/fcimb.2017.00198
  • Dankwa DA, Davis MJ, Kappe SHI, et al. A Plasmodium yoelii Mei2-like RNA binding protein is essential for completion of liver stage schizogony. Infect Immun. 2016 May;84(5):1336–1345. doi: 10.1128/IAI.01417-15
  • Goswami D, Arredondo SA, Betz W, et al. A conserved Plasmodium protein that localizes to liver stage nuclei is critical for late liver stage development. bioRxiv. 2022:2022.12.13.519845.
  • Sack BK, Keitany GJ, Vaughan AM, et al. Mechanisms of stage-transcending protection following immunization of mice with late liver stage-arresting genetically attenuated malaria parasites. PLOS Pathog. 2015 May;11(5):e1004855. doi: 10.1371/journal.ppat.1004855
  • Dienstag JL, Stevens CE, Bhan AK, et al. Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. Ann Intern Med. 1982 May;96(5):575–579. doi: 10.7326/0003-4819-96-5-575
  • Pol S, Driss F, Michel ML, et al. Specific vaccine therapy in chronic hepatitis B infection. Lancet. 1994 Jul 30;344(8918):342.
  • Ho M, Webster HK, Looareesuwan S, et al. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J Infect Dis. 1986;153(4):763–771. doi: 10.1093/infdis/153.4.763
  • McGregor IA, Barr M. Antibody response to tetanus toxoid inoculation in malarious and non-malarious Gambian children. Trans R Soc Trop Med Hyg. 1962;56(5):364–367. doi: 10.1016/0035-9203(62)90005-6
  • Greenwood BM, Bradley-More AM, Palit A, et al. Immunosuppression in children with malaria. Lancet. 1972;i:169–172.
  • Williamson WA, Greenwood BM. Impairment of the immune response to vaccination after acute malaria. Lancet. 1978;1(8078):1328–1329. doi: 10.1016/S0140-6736(78)92403-0
  • Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science. 2006 Dec 8;314(5805):1603–1606.
  • Nyirenda TS, Nyirenda JT, Tembo DL, et al. Loss of humoral and cellular immunity to invasive nontyphoidal Salmonella during current or convalescent Plasmodium falciparum infection in Malawian children. Clin Vaccine Immunol. 2017 Jul;24(7). doi: 10.1128/CVI.00057-17
  • Casares S, Richie TL. Immune evasion by malaria parasites: a challenge for vaccine development. Curr Opin Immunol. 2009 Jun;21(3):321–330. doi: 10.1016/j.coi.2009.05.015
  • Chatterjee D, Lewis FJ, Sutton HJ, et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes. Cell Rep. 2021 Apr 13;35(2):108996.
  • Egan A, Waterfall M, Pinder M, et al. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun. 1997 Aug;65(8):3024–3031. doi: 10.1128/iai.65.8.3024-3031.1997
  • Rathore D, Nagarkatti R, Jani D, et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem. 2005 May 27;280(21):20524–20529.
  • Lee EA, Flanagan KL, Minigo G, et al. Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Eur J Immunol. 2006 May;36(5):1168–1178. doi: 10.1002/eji.200526010
  • D’Ombrain MC, Voss TS, Maier AG, et al. Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. Cell Host Microbe. 2007 Aug 16;2(2):130–138.
  • Steers N, Schwenk R, Bacon DJ, et al. The immune status of Kupffer cells profoundly influences their responses to infectious Plasmodium berghei sporozoites. Eur J Immunol. 2005 Aug;35(8):2335–2346. doi: 10.1002/eji.200425680
  • Loughland JR, Minigo G, Burel J, et al. Profoundly reduced CD1c+ myeloid dendritic cell HLA-DR and CD86 expression and increased tumor necrosis factor production in experimental human blood-stage malaria infection. Infect Immun. 2016 May;84(5):1403–1412. doi: 10.1128/IAI.01522-15
  • Illingworth J, Butler NS, Roetynck S, et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol. 2013 Feb 1;190(3):1038–1047.
  • Sullivan RT, Kim CC, Fontana MF, et al. FCRL5 delineates functionally impaired memory B cells associated with Plasmodium falciparum exposure. PLOS Pathog. 2015 May;11(5):e1004894. doi: 10.1371/journal.ppat.1004894
  • Horne-Debets JM, Faleiro R, Karunarathne DS, et al. PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep. 2013 Dec 12;5(5):1204–1213.
  • Saito F, Hirayasu K, Satoh T, et al. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature. 2017 Dec 7;552(7683):101–105.
  • Xu H, Wipasa J, Yan H, et al. The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J Exp Med. 2002 Apr 1;195(7):881–892.
  • Walther M, Tongren JE, Andrews L, et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity. 2005 Sep;23(3):287–296. doi: 10.1016/j.immuni.2005.08.006
  • Minigo G, Woodberry T, Piera KA, et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLOS Pathog. 2009 Apr;5(4):e1000402. doi: 10.1371/journal.ppat.1000402
  • Skorokhod OA, Alessio M, Mordmüller B, et al. Hemozoin (malarial pigment) inhibits differentiation and maturation of human monocyte-derived dendritic cells: a peroxisome proliferator-activated receptor-gamma-mediated effect. J Immunol. 2004 Sep 15;173(6):4066–4074.
  • Scorza T, Magez S, Brys L, et al. Hemozoin is a key factor in the induction of malaria-associated immunosuppression. Parasite Immunol. 1999 Nov;21(11):545–554. doi: 10.1046/j.1365-3024.1999.00254.x
  • Tall A, Sokhna C, Perrault R, et al. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission. Malaria J. 2009;8:161. doi: 10.1186/1475-2875-8-161
  • Orjih AU, Nussenzweig RS. Plasmodium berghei: suppression of antibody response to sporozoite stage by acute blood stage infection. Clin Exp Immunol. 1980;38:1–8.
  • Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med. 2003;197(2):143–151. doi: 10.1084/jem.20021072
  • Watson F, Shears M, Matsubara J, et al. Cryopreserved sporozoites with and without the glycolipid adjuvant 7DW8-5 protect in prime-and-trap malaria vaccination. Am J Trop Med Hyg. 2022 Feb 28;106(4):1227–1236.
  • Vaughan AM, Kappe SHI. Genetically attenuated malaria parasites as vaccines. Expert Rev Vaccines. 2017 Aug;16(8):765–767. doi: 10.1080/14760584.2017.1341835
  • Müller K, Gibbins MP, Roberts M, et al. Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination. EMBO Mol Med. 2021 Apr 9;13(4):e13390.
  • Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002 Oct 3;419(6906):498–511.
  • Müller DA, Charlwood JD, Felger I, et al. Prospective risk of morbidity in relation to multiplicity of infection with Plasmodium falciparum in São Tomé. Acta Trop. 2001 Feb 23;78(2):155–162.
  • Touray AO, Mobegi VA, Wamunyokoli F, et al. Diversity and multiplicity of P. falciparum infections among asymptomatic school children in Mbita, western Kenya. Sci Rep. 2020 Apr 3;10(1):5924.
  • Gandhi K, Thera MA, Coulibaly D, et al. Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg. 2012 May;86(5):775–781. doi: 10.4269/ajtmh.2012.11-0478
  • Dzikowski R, Templeton TJ, Deitsch K. Variant antigen gene expression in malaria. Cell Microbiol. 2006 Sep;8(9):1371–1381. doi: 10.1111/j.1462-5822.2006.00760.x
  • Ouattara A, Barry AE, Dutta S, et al. Designing malaria vaccines to circumvent antigen variability. Vaccine. 2015 Dec 22;33(52):7506–7512.
  • Chattopadhyay R, Pratt D. Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective. Vaccine. 2017 May 15;35(21):2767–2769.
  • Walk J, Reuling IJ, Behet MC, et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial [journal article]. BMC Med. 2017 Sep 13;15(1):168.
  • USP. Cryopreservation of Cells <1044>. In: USP-NF. Rockville, MD: USP; Sep 27, 2018. Available at https://www.usp.org/sites/default/files/usp/document/our-work/biologics/resources/gc-1044-cryopreservation-of-cells.pdf
  • Jusu MO, Glauser G, Seward JF, et al. Rapid establishment of a cold chain capacity of -60°C or colder for the STRIVE Ebola vaccine trial during the Ebola outbreak in Sierra Leone. J Infect Dis. 2018 May 18;217(suppl_1):S48–s55.
  • Di Giulio G, Lynen G, Morzaria S, et al. Live immunization against East Coast fever–current status. Trends Parasitol. 2009 Feb;25(2):85–92. doi: 10.1016/j.pt.2008.11.007
  • Matthias DM, Robertson J, Garrison MM, et al. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine. 2007 May 16;25(20):3980–3986.
  • Comes M, Bergtora Sandvik K, van de Walle BA. Cold chains, interrupted: the use of technology and information for decisions that keep humanitarian vaccines cool. J Humanit Logist Supply Chain Manag. 2018;8(1):49–69. doi: 10.1108/JHLSCM-03-2017-0006
  • Pambudi NA, Sarifudin A, Gandidi IM, et al. Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs. Energy Rep. 2022 [2022 Nov 1];8:955–972.
  • Richie TL. Interactions between malaria parasites infecting the same vertebrate host. Parasitology. 1988;96(3):607–639. doi: 10.1017/S0031182000080227
  • Nussenzweig RS, Vanderberg JP, Spitalny GL, et al. Sporozoite-induced immunity in mammalian malaria. A review. Am J Trop Med Hyg. 1972;21(5_Suppl):722–728. doi: 10.4269/ajtmh.1972.21.722
  • Nussenzweig RS, Chen D. The antibody response to sporozoites of simian and human malaria parasites: its stage and species specificity and strain cross-reactivity. Bull World Health Organ. 1974;50(3–4):293–297.
  • Sina BJ, Do Rosario VE, Woollett G, et al. Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection. Exp Parasitol. 1993;77(2):129–135. doi: 10.1006/expr.1993.1069
  • Sedegah M, Weiss WW, Hoffman SL. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol. 2007 Nov;29(11):559–565. doi: 10.1111/j.1365-3024.2007.00976.x
  • Inoue M, Tang J, Miyakoda M, et al. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development. Int J Parasitol. 2012 Aug;42(9):859–870. doi: 10.1016/j.ijpara.2012.07.001
  • Mendes AM, Machado M, Goncalves-Rosa N, et al. A Plasmodium berghei sporozoite-based vaccination platform against human malaria. NPJ Vaccines. 2018;3(1):33. doi: 10.1038/s41541-018-0068-2
  • Reuling IJ, Mendes AM, de Jong GM, et al. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Sci Transl Med. 2020 May 20;12(544). doi: 10.1126/scitranslmed.aay2578
  • Arevalo-Herrera M, Vasquez-Jimenez JM, Lopez-Perez M, et al. Protective efficacy of Plasmodium vivax radiation-attenuated sporozoites in Colombian volunteers: a randomized controlled trial. PLoS Negl Trop Dis. 2016 Oct;10(10):e0005070. doi: 10.1371/journal.pntd.0005070
  • White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011 Oct 11;10(1):297.
  • Schafer C, Zanghi G, Vaughan AM, et al. Plasmodium vivax latent liver stage infection and relapse: Biological insights and new experimental tools. Annu Rev Microbiol. 2021 Oct 8;75(1):87–106.
  • Schafer C, Dambrauskas N, Reynolds LM, et al. Partial protection against P. vivax infection diminishes hypnozoite burden and blood-stage relapses. Cell Host Microbe. 2021 May 12;29(5):752–756 e4.
  • Betuela I, Rosanas-Urgell A, Kiniboro B, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis. 2012 Dec 1;206(11):1771–1780.
  • Robinson LJ, Wampfler R, Betuela I, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLOS Med. 2015 Oct;12(10):e1001891. doi: 10.1371/journal.pmed.1001891
  • Moore KA, Simpson JA, Scoullar MJL, et al. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. Lancet Glob Health. 2017 Nov;5(11):e1101–e1112. doi: 10.1016/S2214-109X(17)30340-6
  • World Health Organization. World malaria report 2022. Geneva: World Health Organization; 2022.
  • Bundy DAP, Silva N, Horton S, et al. Child and adolescent health and development: Realizing neglected potential. Child and Adolescent Health and Development. 3rd edition. The International Bank for Reconstruction and Development/The World Bank; 2017p. 1–24. doi: 10.1596/978-1-4648-0423-6_ch1
  • Brooker SJ, Clarke S, Fernando D, et al. Malaria in middle childhood and adolescence. Disease control priorities. Third Vol. 8. Child and Adolescent Health and Development; 2017p. 183–198. doi: 10.1596/978-1-4648-0423-6_ch14
  • World Health Organization. Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in children: a field guide. Geneva: World Health Organization; 2023.
  • Chandramohan D, Zongo I, Sagara I, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021 Aug 25;385(11):1005–1017.
  • Takarinda KP, Nyadundu S, Govha E, et al. Factors associated with a malaria outbreak at Tongogara refugee camp in Chipinge district, Zimbabwe, 2021: a case-control study. Malar J. 2022 Mar 19;21(1):94.
  • World Health Organization. Malaria vaccines: preferred product characteristics and clinical development considerations. 2022.
  • Dabira ED, Hachizovu S, Conteh B, et al. Efficacy, safety and tolerability of pyronaridine-artesunate in asymptomatic malaria-infected individuals: a randomized controlled trial. Clin Infect Dis. 2022 Jan 29;74(2):180–188.
  • Duffy PE. Transmission-blocking vaccines: harnessing herd immunity for malaria elimination. Expert Rev Vaccines. 2021 Feb;20(2):185–198. doi: 10.1080/14760584.2021.1878028
  • World Health Organization. Zeroing in on malaria elimination: final report of the E-2020 initiative. 2021.
  • World Health Organaization. (2021, Oct 6). WHO Recommends Groundbreaking Malaria Vaccine For Children At Risk [News release]. Retrieved from https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk
  • Datoo MS, Natama HM, Somé A, et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1728–1736. doi: 10.1016/S1473-3099(22)00442-X
  • RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015 Apr 23;386(9988): 31–45. doi: 10.1016/S0140-6736(15)60721-8
  • Plowe CV, Alonso P, Hoffman SL. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis. 2009;200(11):1646–1649. doi: 10.1086/646613

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.